{
  "type": "add_node",
  "timestamp": "2025-08-15T02:16:44",
  "processed": false,
  "inputs": {
    "source_article_id": "8P3H88BMH",
    "status": "rejected",
    "reject_category": "company",
    "reject_failure_cat": "industry_vertical"
  },
  "details": {
    "llm_topic_proposal_raw": {
      "motivation": "The article highlights Invivyd's significant revenue growth driven by its COVID-19 monoclonal antibody PEMGARDA, which is crucial for understanding trends in biotech revenue generation and regulatory impacts on market performance.",
      "id": "invivyd",
      "name": "Invivyd",
      "type": "company",
      "level": "main"
    },
    "topic_category": {
      "category": "company",
      "motivation": "The topic is a company, Invivyd, not a macro driver, asset, policy, geography, or industry vertical."
    },
    "relevance_gate": {
      "should_add": false,
      "reason": "Invivyd is a biotech company, an industry vertical, not a macro driver or tradable asset per the policy.",
      "confidence": 0.95,
      "failure_category": "industry_vertical"
    }
  },
  "id": "none"
}